|
Alcohol abuse
|
0.320 |
Biomarker
|
disease |
PSYGENET |
Concerning anxiety disorders and alcohol use disorders, the current findings are preliminary and need further verification to explain the association of ARNTL2, being suggestive only, with social phobia (rs2306073) and with alcohol abuse (rs7958822, rs4964057).
|
22538398 |
2012 |
|
Alcohol abuse
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
Concerning anxiety disorders and alcohol use disorders, the current findings are preliminary and need further verification to explain the association of ARNTL2, being suggestive only, with social phobia (rs2306073) and with alcohol abuse (rs7958822, rs4964057).
|
22538398 |
2012 |
|
Alcohol abuse
|
0.320 |
Biomarker
|
disease |
PSYGENET |
ARNTL2 GT haplotype (rs7958822-rs4964057) associated suggestively with alcohol abuse diagnosis (P = 0.0013).
|
20554694 |
2010 |
|
Alcohol abuse
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
ARNTL2 GT haplotype (rs7958822-rs4964057) associated suggestively with alcohol abuse diagnosis (P = 0.0013).
|
20554694 |
2010 |
|
Bipolar Disorder
|
0.300 |
Biomarker
|
disease |
PSYGENET |
We examined 209 single-nucleotide polymorphisms (SNPs) covering 19 circadian genes (ADCYAP1, ARNTL, ARNTL2, BHLHB2, BHLHB3, CLOCK, CRY1, CRY2, CSNK1E, DBP, NPAS2, NR1D1, PER1, PER2, PER3, RORA, TIMELESS, VIP, and VIPR2) in a sample of 534 MD patients (335 with unipolar major mood depression (MDD) and 199 with bipolar disorder (BD)) and 440 community-based screened controls.
|
20072116 |
2010 |
|
Bipolar Disorder
|
0.300 |
Biomarker
|
disease |
PSYGENET |
Clock genes may influence bipolar disorder susceptibility and dysfunctional circadian rhythm.
|
18228528 |
2008 |
|
Acute-On-Chronic Liver Failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Within ACLF patients, the 2016-MELD, CLIF-C ACLF and Child-Pugh scores showed an AUC of 0.774, 0.734, 0.584 (28-day) and 0.880, 0.771, 0.603 (90-day); for 2016-MELD p = 0.004 (28-day) and p < 0.0001 (90-day).
|
31113608 |
2020 |
|
Acute-On-Chronic Liver Failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
In parallel, the CLIF-C ACLF grade and OF score, estimated at 28- and 90-day mortality, AKI stage, hepatic encephalopathy grade, and liver function tests were lowered (P = 0.001-0.032).
|
31267563 |
2020 |
|
Waist-Hip Ratio
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Acute-On-Chronic Liver Failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A CLIF-C AD Score ≥60 on admission was associated with a higher risk of developing ACLF.
|
30772084 |
2019 |
|
Acute-On-Chronic Liver Failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
The predictive accuracy of the Chronic Liver Failure-Sequential Organ Failure Assessment (CLIF-SOFA) for 28-day mortality was similar to the CLIF Consortium Organ Failure (CLIF-C OF) but significantly higher than the CLIF Consortium ACLF, the Child-Turcotte-Pugh, the model for end-stage liver disease (MELD), the MELD-sodium, the integrated MELD, and the Acute Physiology and Chronic Health Evaluation II.
|
31291342 |
2019 |
|
Acute-On-Chronic Liver Failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Hepatic encephalopathy (HE), gastrointestinal bleeding, AKI, hyperkalemia, elevated total bilirubin (TBIL) and international normalized ratio (INR) values, and higher Model for End-Stage Liver Disease (MELD) and chronic liver failure-sequential organ failure assessment (CLIF-SOFA) scores were independent risk factors for predicting the 90-day mortality in ACLF patients.
|
30937312 |
2019 |
|
Acute-On-Chronic Liver Failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
EASL-CLIF's definition of ACLF was used.
|
31385871 |
2019 |
|
Acute-On-Chronic Liver Failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The Tongji prognostic predictor model score (TPPMs), which set the number of complications as one of the determinants, showed comparable or superior ability to the Chinese Group on the Study of Severe Hepatitis B-ACLF score (COSSH-ACLFs), APASL-ACLF Research Consortium score (AARC-ACLFs), CLIF-C organ failure score (CLIF-C OFs), CLIF-C-ACLF score (CLIF-C-ACLFs), Model for End-Stage Liver Disease score (MELDs) and MELD-sodium score (MELD-Nas) in HBV-ACLF patients, especially in cirrhotic HBV--ACLF patients.
|
31650510 |
2019 |
|
Acute-On-Chronic Liver Failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mortality models were compared to MELD, MELD-sodium, and the CLIF-C ACLF score.
|
31840390 |
2019 |
|
Acute-On-Chronic Liver Failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
The predictive value of nomogram was the strongest compared with CLIF-C ACLF, MELD and MELD-Na and similar to COSSH-ACLF in both the derivation and prospective validation cohorts with APASL ACHBLF, but the CLIF-C ACLF was better in the EASL-CLIF ACHBLF cohort.
|
30241795 |
2019 |
|
Acute-On-Chronic Liver Failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to explore prognostic value of the Chronic Liver Failure-Sequential Organ Failure Assessment (CLIF-SOFA) lung score and to establish an optimal voriconazole regimen for ACLF patients complicated with IPA.
|
29343867 |
2018 |
|
Acute-On-Chronic Liver Failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cumulative survival rates differed significantly between patients with CLIF-C ACLF scores ≤ 58 and those with CLIF-C ACLF scores ≥ 59 after PE (P< 0.05).
|
29880246 |
2018 |
|
Acute-On-Chronic Liver Failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Validation of CLIF-C ACLF score to define a threshold for futility of intensive care support for patients with acute-on-chronic liver failure.
|
30305132 |
2018 |
|
Acute-On-Chronic Liver Failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
It can also distinguish distinct clinical characteristics and prognoses in patients with and without EASL-CLIF ACLF.
|
28456135 |
2018 |
|
Acute-On-Chronic Liver Failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The CLIF-C ACLF or AD scores had an adequate, predictive discrimination ability for mortality at all time points, with Harrel's concordance index-C ranging between 0.64 and 0.65 or 0.64 and 0.68, respectively.
|
28851246 |
2017 |
|
Acute-On-Chronic Liver Failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Liver failure determines the outcome in patients of acute-on-chronic liver failure (ACLF): comparison of APASL ACLF research consortium (AARC) and CLIF-SOFA models.
|
28856540 |
2017 |
|
Acute-On-Chronic Liver Failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
The cut-point for baseline CLIF-C OFs in predicting death was 8.5, with 67% sensitivity, 90% specificity, and AUROC of 0.906 (95% CI: 0.8450-0.9679).The results indicate that short-term mortality is high in patients with ACLF and CLIF Consortium Organ Failure score is superior to MELD, CLIF SOFA, and CLIF-C ACLF in predicting its short-term mortality.
|
28445322 |
2017 |
|
Acute-On-Chronic Liver Failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among patients with ACLF, at 28 d from the diagnosis, CLIF-C ACLF was the only score able to predict mortality significantly better than the reference line, with an AUC (95%CI) of 0.71 (95%CI: 0.54-0.88, <i>P</i> = 0.021).
|
28811718 |
2017 |
|
Acute-On-Chronic Liver Failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
We used ACLF grades according to EASL-CLIF consortium criteria to categorize the cirrhotic patients.
|
28052486 |
2017 |